Pawlotsky J M, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D
Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France.
Hepatology. 2000 Sep;32(3):654-9. doi: 10.1053/jhep.2000.16603.
It was recently recommended that hepatitis C virus (HCV) RNA quantification be used to tailor the duration of combined interferon alfa (IFN-alpha)/ribavirin therapy in patients infected by HCV genotypes 1, 4, and 5. This recommendation has been difficult to implement in the absence of standardized quantitative units for HCV RNA. The aim of this work was to define clinically relevant HCV RNA loads in standardized international units (IU), for use in routine clinical and research applications based on standardized quantitative assays. Two hepatitis C virus RNA quantitative assays were used: (1) the Superquant assay (National Genetics Institute, Los Angeles, CA), for which possibly relevant thresholds were established; and (2) the semi-automated Cobas Amplicor HCV Monitor assay version 2.0 (Cobas v2.0, Roche Molecular Systems, Pleasanton, CA) that measures HCV RNA loads in IU/mL. Quantification in the Cobas v2.0 assay was linear over the entire range of values tested, including viral loads higher than 850,000 IU/mL after 100-fold dilution. The accuracy and precision of the measures in IU/mL were satisfactory with Cobas v2.0. The results obtained with Superquant and Cobas v2.0 correlated (r =.932; P <.0001). A value of 2,000,000 copies/mL (6.3 log(10) copies/mL) with Superquant was converted to nearly 800,000 IU/mL (5.9 log(10) IU/mL). In conclusion, all HCV RNA quantitative assays should give HCV RNA loads in international units and be validated with appropriate calibrated panels; 800,000 IU/mL in any of these assays should be used as the decision threshold to tailor the IFN-alpha/ribavirin treatment duration in patients infected by HCV genotypes 1, 4, and 5.
最近有人建议,对于感染丙型肝炎病毒1、4和5型的患者,应使用丙型肝炎病毒(HCV)RNA定量来调整干扰素α(IFN-α)联合利巴韦林治疗的疗程。在缺乏HCV RNA标准化定量单位的情况下,这一建议难以实施。这项工作的目的是确定基于标准化定量检测的、用于常规临床和研究应用的标准化国际单位(IU)中临床相关的HCV RNA载量。使用了两种丙型肝炎病毒RNA定量检测方法:(1)Superquant检测法(美国加利福尼亚州洛杉矶市国家遗传研究所),为其确定了可能相关的阈值;(2)半自动的Cobas Amplicor HCV Monitor检测法2.0版(Cobas v2.0,美国加利福尼亚州普莱森顿市罗氏分子系统公司),该方法以IU/mL为单位测量HCV RNA载量。Cobas v2.0检测法在整个测试值范围内呈线性,包括100倍稀释后高于每毫升850,000 IU的病毒载量。Cobas v2.0以IU/mL为单位的测量准确性和精密度令人满意。Superquant和Cobas v2.0获得的数据具有相关性(r = 0.932;P < 0.0001)。Superquant检测法测得的每毫升2,000,000拷贝(6.3 log₁₀拷贝/mL)转换后约为每毫升800,000 IU(5.9 log₁₀ IU/mL)。总之,所有HCV RNA定量检测都应以国际单位给出HCV RNA载量,并使用适当的校准样本进行验证;在这些检测方法中,任何一种检测结果为每毫升800,000 IU都应作为确定感染丙型肝炎病毒1、4和5型患者IFN-α/利巴韦林治疗疗程的决定阈值。